WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
Subscribe To Our Newsletter & Stay Updated
